GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cepheid (NAS:CPHD) » Definitions » Altman Z2-Score

Cepheid (Cepheid) Altman Z2-Score : 3.02 (As of May. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Cepheid Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Cepheid has a Altman Z2-Score of 3.02, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Cepheid's Altman Z2-Score or its related term are showing as below:


Cepheid Altman Z2-Score Historical Data

The historical data trend for Cepheid's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cepheid Altman Z2-Score Chart

Cepheid Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cepheid Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cepheid's Altman Z2-Score

For the Diagnostics & Research subindustry, Cepheid's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cepheid's Altman Z2-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cepheid's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Cepheid's Altman Z2-Score falls into.



Cepheid Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Cepheid's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5705+3.26*-0.4366+6.72*-0.0232+1.05*0.8156
=3.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2016:
Total Assets was $847.4 Mil.
Total Current Assets was $629.9 Mil.
Total Current Liabilities was $146.5 Mil.
Retained Earnings was $-370.0 Mil.
Pre-Tax Income was -9.714 + -10.117 + -5.87 + -9.144 = $-34.8 Mil.
Interest Expense was -3.856 + -3.812 + -3.765 + -3.722 = $-15.2 Mil.
Total Liabilities was $466.7 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(629.861 - 146.475)/847.357
=0.5705

X2=Retained Earnings/Total Assets
=-369.982/847.357
=-0.4366

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-34.845 - -15.155)/847.357
=-0.0232

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(380.646 - 0)/466.711
=0.8156

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Cepheid has a Altman Z2-Score of 3.02 indicating it is in Safe Zones.


Cepheid  (NAS:CPHD) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Cepheid Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Cepheid's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cepheid (Cepheid) Business Description

Traded in Other Exchanges
N/A
Address
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
Executives
Thomas D Brown director 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK, LAKE MARY FL 32746-6232
Hollings Renton director
John L Bishop director, officer: Chairman of the Board and CEO
Marc Haugen officer: EVP, Global Ops & Engineering C/O CEPHEID, 904 CARIBBEAN DRIVE, SUNNYVALE CA 94089
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew Miller officer: EVP, CFO 111 MCINNIS PARKWAY, SAN RAFAEL CA 94903
Jim Post officer: EVP, NA Commercial Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453

Cepheid (Cepheid) Headlines

From GuruFocus

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-28-2011

Mario Gabelli Comments on Cepheid

By Holly LaFon Holly LaFon 01-31-2017

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 08-04-2010

Columbia Wanger Sold 2 Stakes in September

By David Goodloe David Goodloe 10-07-2016

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-15-2011

CEPHEID Reports Operating Results (10-K/A)

By gurufocus 10qk 10-01-2009

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2010

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 05-04-2010

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-08-2011

Baron Funds Comments on Cepheid

By Holly LaFon Holly LaFon 02-08-2016